PDCD1 and nasopharyngeal carcinoma: More recently, four different anti-PD-1 antibodies, Pembrolizumab, Nivolumab, Camrelizumab, Toripalimab, and Tislelizumab, have been used to treat RM-NPC and shown to significantly improve survival in a small proportion of the patients (6–11).